FindTrial
Sign In

ACY-1215

DRUG6 trials

Sponsors

Celgene, Acetylon Pharmaceuticals Incorporated, Jennifer Amengual, Columbia University, Dana-Farber Cancer Institute

Conditions

Breast CarcinomaHealthyLymphoid MalignanciesLymphomaMetastatic Breast CancerMultiple MyelomaRecurrent Chronic Lymphoid Leukemia

Phase 1

Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
CompletedNCT01323751
CelgeneMultiple Myeloma
Start: 2011-07-31End: 2016-12-03Target: 120Updated: 2017-04-06
Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma
CompletedNCT01583283
CelgeneMultiple Myeloma
Start: 2012-07-12End: 2021-03-24Updated: 2022-02-23
Alternative 10 mg/mL Liquid Formulation of ACY 1215 (Ricolinostat) in Healthy Subjects
CompletedNCT02088398
Acetylon Pharmaceuticals IncorporatedHealthy
Start: 2014-03-31End: 2014-04-30Updated: 2014-09-11
ACY-1215 for Relapsed/Refractory Lymphoid Malignancies
TerminatedNCT02091063
Jennifer AmengualLymphoid Malignancies, Lymphoma
Start: 2014-04-02End: 2019-05-05Updated: 2024-08-06
ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer
CompletedNCT02632071
Columbia UniversityBreast Carcinoma, Metastatic Breast Cancer
Start: 2016-03-01End: 2020-09-30Updated: 2021-01-07
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
Active, not recruitingNCT02787369
Dana-Farber Cancer InstituteRecurrent Chronic Lymphoid Leukemia
Start: 2016-05-01End: 2027-04-01Updated: 2026-05-19

Related Papers

Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial
2024-08-222 citations
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer.
2022-12-3061 citations
First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma
The Oncologist2021-01-1853 citations
Abstract 2898: Inhibition of HDAC6 as a novel targeted therapy in breast cancer
Cancer Research2018-07-011 citations
Phase IB trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in metastatic breast cancer.
Journal of Clinical Oncology2018-05-203 citations
Abstract OT1-01-10: Multi-center phase IB trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in unresectable or metastatic breast cancer
Cancer Research2017-02-151 citations
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.
2016-09-17152 citations
Mechanisms of Acquired Drug Resistance to the Isoform Selective HDAC6 Inhibitor Ricolinostat Reveals Markedly Upregulated Elements of the BTK Pathway Revealing Rational Drug : Drug Combinations
Blood2015-12-03
Development and Characterization of Two Lymphoma Cell Lines Resistant to the Selective HDAC6 Inhibitor Ricolinostat (ACY-1215) As a Tool to Better Understand the Biology of HDACs on Lymphoma
Blood2014-12-06
Abstract 5456: ACY-1215, a selective inhibitor of HDAC6, synergizes with immunomodulatory drugs (IMiDs) to induce apoptosis of multiple myeloma (MM) cells
Cancer Research2014-10-01
ACY-1215, a First-In-Class Selective Inhibitor Of HDAC6, Demonstrates Significant Synergy With Immunomodulatory Drugs (IMiDs) In Preclinical Models Of Multiple Myeloma (MM)
Blood2013-11-1511 citations
Preclinical Combination Of The Oral Investigational Agents ACY-1215, a Selective HDAC6 Inhibitor, and Ixazomib, a Proteasome Inhibitor, Demonstrates Combination Benefit In Multiple Myeloma Cell Lines and Xenograft Models
Blood2013-11-152 citations
Inhibition Of HDAC6 In Combination With Targeted Agents Results In Broad Synergistic Decreases In Viability In Non-Hodgkin’s Lymphoma (NHL) Cells
Blood2013-11-15